Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct;94(4):635-639.
doi: 10.1007/s00280-024-04642-y. Epub 2024 Mar 2.

Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia

Wenqiang Qu #  1 , Jialing Lu #  2 , Yujie Ji  1 , Zhewei He  1 , Mengjia Hou  3 , Dongyang Li  3 , Yan Yang  3 , Dan Liu #  4 , Suning Chen #  5
Affiliations
Case Reports

Successful use of Palbociclib combined with Venetoclax and Azacitidine in an adult with refractory/relapsed therapy-related acute myeloid leukemia

Wenqiang Qu et al. Cancer Chemother Pharmacol. 2024 Oct.

Abstract

Background: Therapy-related acute myeloid leukemia (t-AML) is considered high risk as it related to prior exposure to cytotoxic chemotherapy agents for solid tumors or hematologic malignancies. Compared with de novo AML, t-AML is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. Many efforts have been devoted to improving the overall but with limited success, and novel strategy is thus highly needed.

Case description: We reported one patient with refractory/relapsed t-AML was successfully treated with Palbociclib combined with Venetoclax and Azacytidine (AZA). In this case, a 47-year-old patient with t-AML recurred during Venetoclax in combination with AZA therapy. However, the patient achieved morphological, immunophenotypic and molecular complete remission again after Palbociclib combined with Venetoclax and AZA.

Conclusions: Although only one successful case is presented here, three-drug combination regimens should be considered as another treatment option for t-AML in the future.

Keywords: Azacitidine; CDK6; Palbociclib; Therapy-related acute myeloid leukemia; Venetoclax.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179–198 - DOI - PubMed
    1. Almeida AM, Ramos F (2016) Acute myeloid leukemia in the older adults. Leuk Res Rep 6:1–7 - PubMed - PMC
    1. Winer ES, Stone RM (2019) Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol 10:2040620719860645 - DOI - PubMed - PMC
    1. Cluzeau T, Sebert M, Rahmé R et al (2021) Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol 39(14):1575–1583 - DOI - PubMed - PMC
    1. Granfeldt Østgård LS, Medeiros BC, Sengeløv H et al (2015) Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33(31):3641–3649 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources